5 results on '"Mastrolia, Maria Vincenza"'
Search Results
2. Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity.
- Author
-
Taddio, Andrea, Paolera, Sara Della, Abbagnato, Luisa, Agrusti, Anna, Badolato, Raffaele, Biscaro, Francesca, Caorsi, Roberta, Consolaro, Alessandro, Dellepiane, Rosa Maria, Fabi, Marianna, Floretta, Ilenia, Gattorno, Marco, Giangreco, Manuela, Torre, Francesco La, Maggio, Maria Cristina, Mambelli, Lorenzo, Mauro, Angela, Mastrolia, Maria Vincenza, Meneghel, Alessandra, and Montin, Davide
- Subjects
PREVENTION of heart diseases ,RESEARCH ,METHYLPREDNISOLONE ,STATISTICS ,MULTISYSTEM inflammatory syndrome ,BIOLOGICAL products ,CONFIDENCE intervals ,HEART ,INTERLEUKIN-1 ,ACQUISITION of data ,RETROSPECTIVE studies ,ANTIRHEUMATIC agents ,SEVERITY of illness index ,TREATMENT effectiveness ,INTRAVENOUS immunoglobulins ,TREATMENT failure ,MEDICAL records ,DESCRIPTIVE statistics ,RESEARCH funding ,DEATH ,ODDS ratio ,EARLY medical intervention ,LONGITUDINAL method ,PATIENT safety ,CHEMICAL inhibitors ,EVALUATION ,CHILDREN - Abstract
Objective The main aim of this study was to define the best treatment option for multisystem inflammatory syndrome in children (MIS-C) and to analyse the role of anakinra. Methods This is a multicentre retrospective cohort study. Patients were treated according to the attending physician's decision. The patients were divided into four groups on the basis of the first treatment at time of admittance: (i) IVIG, (ii) IVIG and methylprednisolone (≤2 mg/kg/day), (iii) IVIG with high-dose methylprednisolone (>2 mg/kg/day) and (iv) anakinra with or without IVIG and/or methylprednisolone. Primary outcomes were defined as the presence of at least one of the following features: death, the failure of initial treatment, meaning the need for additional treatment for clinical worsening and cardiac involvement at the end of follow-up. Results Two hundred thirty-nine patients were recruited. At univariate analysis, persistent heart involvement at discharge was more frequent in those not receiving anakinra as initial treatment (3/21 vs 66/189; P = 0.047). After comparisons between the four treatment regimens, adjusting for the propensity score, we observed that early treatment with anakinra was associated with a lower probability of developing persistent heart disease at the end of follow-up (odds ratio: 0.6; 95% CI: 0.4–1.0). Conclusion We report that early treatment with anakinra is safe and very effective in patients with severe MIS-C. In addition, our study suggests that early treatment with anakinra is the most favourable option for patients with a higher risk of developing a severe disease outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review.
- Author
-
Mastrolia, Maria Vincenza, De Cillia, Camilla, Orlandi, Michela, Abu-Rumeileh, Sarah, Maccora, Ilaria, Maniscalco, Valerio, Marrani, Edoardo, Pagnini, Ilaria, and Simonini, Gabriele
- Subjects
MULTISYSTEM inflammatory syndrome in children ,COVID-19 ,SARS-CoV-2 ,VACCINATION of children ,VACCINATION ,CORONAVIRUS diseases - Abstract
This narrative review aims to report the main clinical manifestations, therapeutic strategies, outcomes, and complications of acute SARS-CoV-2 infection in childhood and to summarize the data relating the SARS-CoV-2 vaccination efficacy and safety in pediatric age. SARS-CoV-2 infection mostly occurs asymptomatically in the pediatric population, while multisystem inflammatory syndrome in children (MIS-C) represents the most severe coronavirus disease 2019 (COVID-19)-related illness, a life-threatening event with a high morbidity rate. After the development of SARS-CoV-2 vaccines and their subsequent approval in children, the rate of infection as well as the number of its related complications have shown a drastic decrease. Fully vaccinated children are protected from the risk of developing a severe disease and a similar protective role has been observed in the reduction of complications, in particular MIS-C. However, long-lasting immunity has not been demonstrated, booster doses have been required, and reinfection has been observed. With regards to vaccine safety, adverse events were generally mild to moderate in all age groups: local adverse events were the most commonly reported. Nevertheless, a potential association between SARS-CoV-2 vaccine and the subsequent development of inflammatory manifestations has been suggested. Myocarditis has rarely been observed following vaccination; it appeared to be more frequent among adolescent males with a mild clinical course leading to a complete recovery. SARS-CoV-2 vaccine-related MIS-C cases have been described, although a univocal definition and an exact time interval with respect to vaccination has not been reported, thus not establishing a direct causal link. Current evidence about COVID-19 vaccination in children and adolescents suggest that benefits outweigh potential risks. Long-term data collection of the post-authorization safety surveillance programs will better define the real incidence of SARS-CoV-2 vaccine-related complications in the pediatric population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Thrombotic Events in MIS-C Patients: A Single Case Report and Literature Review.
- Author
-
Maniscalco, Valerio, Niccolai, Rachele, Marrani, Edoardo, Maccora, Ilaria, Bertini, Federico, Pagnini, Ilaria, Simonini, Gabriele, Lasagni, Donatella, Trapani, Sandra, and Mastrolia, Maria Vincenza
- Subjects
THROMBOLYTIC therapy ,THROMBOSIS risk factors ,THROMBOSIS ,INTENSIVE care units ,MULTISYSTEM inflammatory syndrome ,PULMONARY embolism ,VENTRICULAR ejection fraction ,PEDIATRICS ,HEPARIN ,HOSPITAL care of children ,CENTRAL venous catheters ,DISEASE complications ,CHILDREN - Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic hyperinflammatory disorder that is associated with a hypercoagulable state and a higher risk of thrombotic events (TEs). We report the case of a 9-year-old MIS-C patient with a severe course who developed a massive pulmonary embolism that was successfully treated with heparin. A literature review of previous TEs in MIS-C patients was conducted (60 MIS-C cases from 37 studies). At least one risk factor for thrombosis was observed in 91.7% of patients. The most frequently observed risk factors were pediatric intensive care unit hospitalization (61.7%), central venous catheter (36.7%), age >12 years (36.7%), left ventricular ejection fraction <35% (28.3%), D-dimer >5 times the upper limit of normal values (71.9%), mechanical ventilation (23.3%), obesity (23.3%), and extracorporeal membrane oxygenation (15%). TEs may concurrently affect multiple vessels, including both arterial and venous. Arterial thrombosis was more frequent, mainly affecting the cerebral and pulmonary vascular systems. Despite antithrombotic prophylaxis, 40% of MIS-C patients developed TEs. Over one-third of patients presented persistent focal neurological signs, and ten patients died, half of whom died because of TEs. TEs are severe and life-threatening complications of MIS-C. In case with thrombosis risk factors, appropriate thromboprophylaxis should be promptly administered. Despite proper prophylactic therapy, TEs may occur, leading in some cases to permanent disability or death. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Neuro-PIMS-TS: a single case report and review of the literature.
- Author
-
Scarcella, Antonio, Mastrolia, Maria Vincenza, Marrani, Edoardo, Maccora, Ilaria, Pagnini, Ilaria, and Simonini, Gabriele
- Abstract
Neurological manifestations related to SARS-CoV-2 infection in adults have been largely reported since the beginning of the pandemic. Subsequent large-scale studies involving children confirmed the occurrence of neurological symptoms associated with SARS-CoV-2 infection also among paediatric patients, especially in the context of paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS). At this regard, we report the challenging case of a 10-month-old baby with PIMS-TS complicated by acute cerebral oedema successfully treated with intravenous immunoglobulins, corticosteroids and anakinra. Our results, combined with the evidence of larger case series suggest that higher inflammatory burden is more frequent in patients with neuro PIMS-TS. As regards neuroimaging, neuroimmune disorders are found to be more common during acute COVID-19, MERS is more frequent during PIMS-TS. Distinct immune mechanisms may underlie these different types of neurological involvement, which are yet to be understood. Further studies are required to better define the physiopathology of neuro PIMS-TS and its possible therapeutical implications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.